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inhibitors were associated with increased survival regardless of LVSF. the relationship 
was lees pronounced in patients with preserved LVSF (p<O.Ol). 
Conclusions: Although older patients hospitalized with heart failure and normal LVSF 
have belter survival than those with impaired LVSF, mortality rates are high in all groups. 
ACE-inhibitors attenuate the relationship between reduced LVSF and Increased morial- 
ity. 
Normal Mild Moderate Severe LVSF not 
” 
Crude 1 -year 
mortality 
Adjusted HA 
(95% Cl) 
(--) ACE-treated 
Adjusted HR 
(95% Cl) 
(c) ACE-treated 
1038-89 
LVSF LVSD LVSD LVSD documented 
7,140 2,875 4,115 5,846 12,015 
27% 31% 34% 41% 41% 
1.00 1.22 1.30 1.65 1.37 
(1.10, (1.18, 1.44) (1.50, (1.28, 1.47) 
1.36) 1.80) 
1 .oo 1.07 1.20 1.45 1.30 
(0.95, (1.08.1.33) (1.32,1.59 (1.21, 1.43) 
1.21) ) 
Lefi Atrial Volume Is More Strongly Associated With 
Prevalent Congestive Heart Failure and Predictive of 
Incident Congestive Heart Failure in the Elderly Than 
Doppler Mitral Inflow Velocities or Deceleration Time 
John S. Gotrdiener. Dalane W. Kitzman, Gerard P. Aurigemma, Alice M. Arnold, Cheryl 
S. Egher, Karen M. Fowle, Jeffrey C. Hill, St. Francis Hospital, Roslyn, NY, NHLBI, 
Bethesda, MD 
In elderly pts, diastolic dysfunction presumably accounts for the large proportion (approx. 
50% of our cohort) of heart failure (HF) with normal systolic function (diastolic HF). Both 
LA size and Doppler parameters of L V diastolic filling are commonly abnormal in HF.We 
evaluated the relative contribution of LA volume (vol)(ZD echo ellipsoid model), mitral 
inflow deceleration (DECEL) time, early (Epk)and late (Apk) peak velocities of mitral 
inflow, as well as LV ejection fraction (EF) for association with prevalent HF and for pre- 
diction of incident HF. Methods: Within the Cardiovascular Health Study. a community- 
based study of cardiac risk in individuals > age 85, we did a case control study of 636 
participants (ppts) (av age 79+/-6 yrs, range 68-99) of whom 121 had HF (prevalent HF) 
at the time of echo evaluation, 179 developed HP within 5 yrs of the baseline echo (inci- 
dent HF), and 336 were age and gender matched controls. Odds ratios were calculated 
in a multivariate model adjusting for age, sex, prevalent and subclinical CV disease, dia- 
betes, hypeltension, height, weight, and atrial fibrillation. Results: see table. Conclusion: 
LAvol is associated with prevalent CHF and is predictive of incident CHF independently 
of LV systolic function, and independently of mitral inflow velocities, deceleration time, as 
well as clinical covariates. While Apk velocity has associative and predictive value, Epk 
and DECEL time do not. 
Odds Ratios (95% C.I.) 
CHF LAvol Decel time E velocity A velocity &F 
Prevalent 3.7(2.3-6.0)’ .9(.6-1.4) 1.1(.7-1.7) 1.5(1 .O-2.3) 7(3-l 6) 
* 
Incident 2.7(1.9-3.8) 1.1(.9-1.4) l.l(.E-1.4) 1.3(1.0-l .8) 2.4(1.2-4.8) 
$ $ 
‘p,<.OOl ,$pc.O4. Odds ratios per parameter S.D. except for EF which was expressed 
as a categorical variable -decreased vs normal. 
1038-70 Diastolic Dysfunction: An Important Predictor of 
Survival in Patients With Preserved Systolic Function 
Richard V. Milani. Carl J. Lavie, Mandeep R. Mehra, Josh Kurtz, Hector 0. Ventura, 
Ochsner Clinic Foundation, New Orleans, LA 
Background: Diastolic dysfunction (DD) carries a poor prognosis when identified in 
patients (pts) with reduced systolic function (SF). However, little is known regarding out- 
come in pts with diastolic filling abnormalities and preserved SF. 
Methods: We assessed diastolic filling and mortality in 7,216 pts (2,885 pts < 50 years, 
2,536 pts 50-70 years, and 1,795 pts > 70 years) with preserved SF (EF >/= 50%) 
referred for echo (mean follow-up of 3.1 years). DD was categorized as either relaxation 
abnormality, pseudonormalization, or restrictive filling panem by standard Doppler 
echocardiographic criteria. 
ResuI1s: DD was extremely prevalent in all age groups, occurring in 40%, 44%. and 70% 
of pts under age 50, 50-70, and > 70 years, respectively. Although EF and BMI were sim- 
tlar in pts with and without DD for all age groups. marked increases in mortality were 
observed in pts with DD (2.fold increased mortality I” pts < 70 years, and 38% increased 
mortality in pts > 70 years; see figure). All categories of DD had similar increases in rnor- 
tality. 
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Conclusions: DD is highly prevalent in pts with preserved SF, increases with age, and is 
associated with a marked increase in mortality. 
1038-71 Heart Failure and/or Left Ventricular Systolic 
Dysfunction Complicating Myocardial Infarction Is 
Common and Accounts for the Majority of In-Hospital 
Myocardial Infarction Mortality: Results of the VALIANT 
Registry 
Eric J. Velazauez. W. Douglas Weaver, Paul W. Armstrong, Rakhi Kilaru, Rafael Diaz. 
Harvey D. White, Wiek H. van Gilst, Jiri Spat, Christopher M. O’Connor, Gary S. Francis, 
Helmut Drexler, Viatcheslav Y. Mareev, Aldo P. Maggioni, Jeffrey D. Leimberger, Marlin 
Myers, Marc Henis, Robert M. Califf, Duke Clinical Research Institute, Durham, NC 
Background: We designed a registry as an adjunct to the VALsartan In Acute myocar- 
dial iNfarcTion (VALIANT) trial to define the incidence of heart failure (HF) and/or left 
ventricular systolic dysfunction (LVSD) prior to discharge following myocardial infarction 
(MI) and lo determine its incremental mortality risk. 
Methods/Results: The VALIANT registry enrolled 5,592 consecutive Ml pts (85 hospi- 
tals. 9 countries) from 200&2001 during prearranged screening periods, with follow-up 
until in-hospital death or discharge. Overall in-hospital modality was 6.8%. Of the MI pts 
entered in cur registry. 42% (n = 2,352) had HF and/or LVSD defined by either clinical or 
radiographic signs of HF and/or LVSD imaging evidence. Selected outcome differences 
are presented (Table). A multivariable logistic model for in-hospital mortality was devel- 
oped (global x 2 = 479.29; C-Index = 0.811). Adjusting for baseline risk, HF and/or LVSD 
was associated with a hazard ratio of 4 39 (95% Cl 3.33 - 5.84). Among HF and/or LVSD 
pts, 34.2% received angiotensin-converting enzyme (ACE) inhibitors and 58.0% beta 
blockers within 24 hours after presentation; 31.4% underwent percutaneous and 11 .O% 
surgical revascularization before discharge. 
Conclusions HF and/or LVSD cccurs in a sizeable minority of contemporary Ml pts and 
accounts for the vast majority of deaths. ldentlfying these pts during the ccurse of Ml 
could trigger mere intensive medical therapy. including revascularization, than that 
observed in the registry. 
Outcomes by In-Hospital HF and/or LVSD Development 
Atrial fibrillation. % 
Stroke. % 
Recurrent MI, % 
Mortality, % 
Mean length of stay, 
days 
HF and/or LVSD (n = No HF and/or LVSD (n = 
2,352) 3,240) 
16.3 7.1 
2.2 0.9 
2.5 1.4 
12.9 2.2 (p < 0.001) 
12.0 7.6 
1038-72 Are NT-Pro Brain Natriuretic Peptides Related to 
Systolic and Diastolic Left Ventricular Function at 
Baseline and During Antihypertensive Treatment? The 
LIFE Study 
Kristian Wachtell. Michael H. Olsen, Christian Tuxen. Lia E. Bang, Christian Hall, Per R. 
Hildebrandt. Hans Ibsen. Jens E. Rokkedal, Richard 6. Devereux, Glostrup University 
Hospital, Glostrup, Denmark, The Weill Medical College of Cornell University, New York, 
NY 
Background: NT-pro-brain natriuretic peptide (NT-pro-BNP) has been shown to predict 
systolic left ventricular (LV) function in patients with congestive heart failure (CHF). Fur- 
thermore, LV function is related lo LV mass and wall stress. It remains unclear whether 
NT-pro-BNP IS related to systolic or diastolic LV function in hypertensive patients without 
CHF and whether this relation is independent of wall stress and LV mass. 
Methods: Clinical, laboratory and echocardiographic variables were assessed in 184 
hypertensive patients with ECG LV hypertrophy. aged 55-80 (mean 66*7 years) at base- 
line after 2 weeks’ placebo and after one year of systematic antihypertensive treatment. 
NT-pro-BNP was measured by immunoassay (Elecsys proBNP). 
Results: NT-pro-BNP at baseline was negatively related to endocardial (EFS. r=-0.251) 
and midwall fractional shortening (MWS, r=-0.245. both p=O.OOl). With adjustment for 
circumferential end-systolic stress, MWS (p=-0.155, ~~0.05) but not EFS (@=-0.028, NS) 
remained related to NT-pro-BNP. However, when taking LV mass wall stress into 
account there was only a trend towards a relation between NT-pro-BNP and MWS (p=- 
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0.138, p=O.O64). NT-pro-BNP correlated with mitral valve E/A ratio (r=0.243, p=O.OOl) 
but not isovolumetric relaxation time (r=0.044. NS) or deceleration time (r=-0.044, NS). 
NT-pro-BNP remained correlated to E/A-ratio (p=O.195, p<O.Ol) with adjustment for cir- 
cumferential end-systolic stress. However, when taking LV mess and wall stress into 
account there was only a trend towards a relation between NT-pro-BNP and mitral valve 
E/A ratio (&0.133, p=O.O71). Change in NT-pro-BNP during 1 year of treatment did not 
correlate with changes in EFS (r=-0.040), MWS (r=-0.074), E/A-ratio (r=O.O08), isovolu- 
mic relaxation time (r=-0.04) or mitral valve e-point deceleration time (r=O.O37. all NS). 
Conclusion: NT-pro-BNP maybe related to LV contractiliy and filling independent of LV 
mass and wall stress in hypertensive patients with ECG LV hypertrophy at baseline. 
However, there was no wall-stress-independent relation between NT-pro-BNP and LV 
pump function. Furthermore, change in NT-pro-BNP over time was not related to 
changes in LV function. 
1038-73 Heart Failure in the Community and in Hospitals: 
Selection and Survival of Patients in Different Settings 
Federica De Giuli. Marlin R. Cowie, Kay-Tee Khaw, Goerge C. Sutton, Roberto Ferrari, 
Philip A. Poole-Wilson, S. Maugeri Foundation IRCCS, Gussago (BS), Italy, NHLI, 
London, United Kingdom 
The aim of the study was to compare the characteristics and 3.year survival data of 
patients (Pts) with diagnosis of heart failure (HF) made in the community and in hospitals 
ln the UK. Methods: Three populations (>=45years) were studied: HFa, 6478 pts from 
the General Practice Research Database (with data from 696884 persons) with new HF 
diagnosis clearly stated by 525 GPs, according to their clinical judgment; HiIHF, 225 Pts 
from the Hillingdon study, with new HF diagnosis made by an expert panel of cardiolo- 
gists, applying the ESC criteria; NetHF, 1929 Pts screened for the Network trial, with HF 
diagnosis confirmed by hospital cardiologists according to their clinical judgment. Stan- 
dardized mortality ratio (SMR) at 1 -year was calculated using as reference population the 
1994 UK age and sex specific death rates (the reference population being l).Results: 
Incidence rates (cases/l000 person-years) were 9.6 and 8.9 in HFa and 3.7 and 4.7 in 
HiIHF, I” women and men, respectively. NetHF were mostly chronic cases. Proportions 
of women were 55.5, 47.1 and 37.5 in HFa, HilHF and NetHF, respectively (’ p.zO.02, 
fp<O.OOl. $pcO.Ol). Mean survival (months-95%CI) was 23.8 (23.4-24.1) for HFa. 21.7 
(19.6-23.7) for HilHF and 31.8 (31.3-32.3) for NetHF(’ p=O.25, f < 0.001, $cO.OOl).. l- 
year SMR (95% Cl) was 14.7 (13.9-15.7) for HFa, 15.2 (11.1-20.7) for HilHF and 3.2 
(2.4-4.3) for NetHF. Both HFa and HilHF (incident cases) had en especially high mortality 
in the first 3 months of follow-up that was not seen in NetHF (chronic cases).Conclu- 
sions: There is a descending rank order I” mean age and proportion of wmen in HF Pts 
seen in the community, in hospitals and those screened for trials. Chronic ceses, which 
are usually studled in trials, represent survivors from the high mortality observed in the 
first 3 months after diagnosis. Both the clinical judgment of GPs and the rigorous applica- 
tion of ESC criteria seem to lead to the detection of severe cases with similar survival in 
both absolute terms and in shape of the survival culves.(’ indicates HFa vs. HiIHF; f, 
HFa vs. NetHF; $, HilHF vs. NetHF). 
1038-74 Does the Prevalence of Atrial Fibrillation Vary by Race 
in Patients With Heart Failure? The Epidemiology, 
Practice, Outcomes, and Costs of Heart Failure 
(EPOCH) Study 
Bernice Rue Angela M. Capra, Nancy G. Jensvold, Alan S. Go, Veterans Administration -I 
Medical Center, San Francisco, San Franc~sco, CA, Kaiser Permanente, Oakland, CA 
Background: The association between heart failure (HF) and atrial fibrillation (AF) is 
well known but the risk factors predisposing to AF in the setting of HF are not well under- 
stood. It has been postulated that among patients with HF, blacks may have a lower 
prevalence of AF compared with whites, but this has not been clearly defined along with 
the potential factors that may explain any observed racial difference. 
Methods: We performed a cross-sectional analysis of the association between race and 
AF in a random sample of adults hospitalized with HF (July 1999.June 2000). HF was 
confirmed using Framingham Heart Study criteria. Data on demographic characteristics, 
comorbid conditions, vital signs at presentation. prior medication use, and left ventricular 
systolic function status were obtained from medical records and automated databases. 
Prevalent AF was defined as AF or atrial flutter documented by electrocardiogram during 
hospitalization and/or by medlcal history. We assessed the independent relationship 
between race and AF using multivariable logistic regression. 
Results: Among 1373 patients (223 blacks, 1150 white) hospitalized with confirmed HF, 
the prevalence of AF was 34.0% (95% Cl: 31.4% to 36.4%). Blacks were more likely than 
whites to be younger (mean age 67 vs. 74 yrs, P<O.OOl) and to have hypertension 
(75.3% vs. 62.4%, P<O.OOl) and prior HF (64.6% vs. 54.9%, P<O.Ol). Blacks were also 
less likely to have a history of coronary disease, hypothyroidism, valve replacement, or 
revascularization, or to be taking digoxin or a beta-blocker on admission. Blacks had a 
significantly lower prevalence of AF (19.7%) compared with whites (38.3%, P<O.OOl). 
After adjustment for nsk factors for AF and other potential confounders, blacks had 35% 
decreased odds of having AF (adjusted odds ratio 0.65, 95% Cl: 0.43-0.97) compared 
with whites. 
Conclusion: In a large contemporary cohort of adults with heart failure, atrial fibrillatwm 
was a c~mrn~n complication but was significantly less ccmrn~n among blacks compared 
with whites. Ractal variation was not explaIned by differences in traditional risk factors for 
atrial fibrillation, presumed heart failure etiology or severity, or medical management. 
1038-75 Sex Differences in Heart Failure: Report From a Large 
Community-Based Cohort 
Edward F. Philbin. 111 Donna Phelan. Mikhail Torosoff. Albany Medical College, Albany, 
NY 
Background: The extent to which wmen differ from men with respect to clinical presen- 
tation, treatment and outcomes in heart failure (HF) is debated. 
Methods: We queried a HF registry compiled from consecutive HF admissions to IO 
community hospitals. Demographics, clinical characteristics, treatment variables and out- 
comes were compared by sex. 
Results: Vital status 6 months after hospital admission was known for 2,506 patients. Of 
these, 1,304 (56%) were women. Mean functional class at admission and the prevalence 
of atrial fibrillation and prior HF were equivalent. Women were older (77.1 vs 73.6 years), 
more often nursing home residents (17 vs 9%) and less often received care from cardiol- 
ogists (14 vs 20%). Women had higher mean ejection fraction (0.39 vs 0.32) and more 
often had diastolic HF (52 vs 34%). lschemic cause of HF was documented less often 
among women (31 vs 43%). Women had lower mean serum creatinine and hematocrit. 
Women received catheterization (10 vs 14%), exercise testing (8 vs 11%) and coronary 
revascularization (4 YS 7%) less often (all PcO.05). Other diagnostic studies were per- 
formed equally. At discharge women less often received ACE inhibitors (57 vs 63%) and 
digoxin (49 vs 54%). Hospital stay was longer for women (7.5 vs 6.9 days) (all P<O.O5). 
Hospital mortality was equivalent (8.5 vs 6.0%). Women were less likely to die during the 
6 months following discharge (15.2 vs 18.4%, P=O.O3). Thus, crude 6.month mortality 
trended lower among women (21.3 YS 24.0%, P=O.lZ). Sex was borderline predictive of 
better survival using the Kaplan-Meier method (P=O.ll) and a proportional hazards 
model to account for age and other factors (P=O.l9). In follow-up, wmen were slightly 
less likely to have rehospitalization for HF (24 vs 26%, P=O.27) or any cause (42 YS 45%, 
P=O.O9). The combined endpoint of death or readmission occurred less often among 
women (52 “s 57%, P=O.O2). 
Conclusions: In this community-based HF cohort, clear sex-related trends emerge. 
Women are older and mcxe often have diastolic HF. They receive a different standard of 
care with respect to medications and referral to specialists. In spite of this, women have 
comparable or better clinical outcomes during and after hosptialization for HF. 
1038-76 Gender-Related Differences in Neurohormonal Plasma 
Levels 
Sylvie A. Ahn, Ronald Van Beneden, Jean-Marie Ketelslegers, Hubert G. Pouleur Michel I- 
F. Rousseau University of Louvain, Brussels, Belgtum -I 
Background :Age is known to affect plasma concentrations of cardiac neurohormonal 
markers used in the evaluation of congestive heart failure, but little is known about gen- 
der-related effects. 
Methods :Accordingly, we compared the plasma levels of atrial natriuretic peptide (N- 
proANF), brain natriuretic peptide (BNP), big endothelin-1 (big ET-l) and angiotensln II 
(All) in 92 healthy subjects (46 females, age 30 to 70 years; 46 males, age 30 to 69 
years). Except for oral contraceptive or hormone replacement therapy, no subject was 
taking chronic medication. 
Results :Overall, mean plasma levels of N-proANF (322 vs 259’ pg/mL). BNP (6.3 YS 
4.5’* pg/mL) were higher in women than in men, while All levels were higher in men 
(10.1 vs 13.5’ pg/mL). Plasma levels of big ET-1 were similar in both groups (4.3 vs 4.1 
pg/mL). 
However, when stratified for age (c or > 50 years), it appears that the increase in natri- 
uretic peptides in women becomes mire evident with aging, while the reverse is true for 
All in men. By contrast, big ET-1 levels seem unaffected by age (see table). 
COnChSiOn :Normal values of N-proANF, BNP and All are affected by age and sex. 
These variations are to be taken into account when using neurohormonal cardiac mark- 
ers for diagnostic purpose. In this perspective, changes in big ET-l, which is more stable 
accr~ss gender and age, should be easier to interpret. 
Data (pg/mL) are means (*SD); *p<O.OS, **p<O.Ol 
N Age N-proANF BNP Big Et-l All 
Male <50 
Female ~50 
Male >50 
Female >50 
24 38*6 230+85 3.9*0.7 4.li7.0 13.0’+5.3 
23 40+6 242+64 4.3tl.l 4.4-0.8 10.0*4.5 
22 58*5 292*117 5.2+2.2 4.2zto.9 14.1+8.0 
23 60+6 402’*174 8.3”*2.4 4.lztO.7 10.5*7.5 
1038-77 The Prevalence of Diastolic Heart Failure in the 
Community 
Gawn I. Galasko, Roxy Senior, Avijtt Lahiri. Northwick Park Hospital, London, United 
Kingdom 
Background Heart failure is placing an increasing burden on the community. The Euro- 
pean Study Group on Diastolic Heart Failure has recently Issued guidelines for the diag- 
nosis of diastolic heart failure (DHF) (EurHeatiJ 1998. 19: 990), which may underlie up 
to 50% of all cases. No studies have looked at the prevalence of DHF in the community 
using these criteria. Accordingly this study was undertaken to assess this further in a 
community in North London. Methods 1403 subjects 245 years old were chosen at rsn- 
dom from 7 representative general practices and invited to undergo a questionnaire, clin- 
ical examination, ECG. echocardiogram and plasma N-terminal-proBNP (NTB) levels 
(Elecys, Roche Diagnostics). DHF was diagnosed according to criteria set by the Study 
Group namely all three of: symptoms of congestive heart failure in the absence of signifi- 
cant lung disease andfor signs of congestive heart failure; left ventricular ejection fraction 
